ObjectiveTo verify the therapeutic efficacy of acupuncture plus speech training and psychological intervention in treating dysarthria in hepatolenticular degeneration (Wilson’s disease).MethodSixty patients were randomized into a control group, a treatment group, and a combined group, 20 in each group. The three groups all received conventional treatments including removal of copper, liver protection, and brain protection, based on which, the control group also received speech training, the treatment group received acupuncture based on the treatments given to the control group, and the combined group received psychological intervention based on the treatments given to the treatment group.ResultAfter 2-month treatment, in comparing the Frenchay Dysarthria Assessment, the combined group showed a more significant improvement than the treatment group and control group (P<0.05); the total effective rate was 75% in the combined group, versus 25% in the treatment group and 10% in the control group, and the total effective rate of the combined group was significantly higher than that of both treatment group and control group (P<0.05).ConclusionAcupuncture plus speech training and psychological intervention can markedly improve the dysarthria symptoms of patients with Wilson’s disease, and recover their speech function and help them to go back to society.

OBJECTIVE To evaluate the safety of fondaparinux in pregnancy and provide reference for its rational clinical application. METHODS A search was conducted in databases including CNKI， Wanfang， PubMed， Embase， and Elsevier （the search time was from the construction of the database to December 17， 2024） to collect case report literature on fondaparinux use during pregnancy. Patient demographic information， fondaparinux use during pregnancy， concomitant medications， clinical manifestations， and treatment details were extracted for descriptive statistical analysis. RESULTS A total of 17 case reports regarding the use of fondaparinux during pregnancy were collected， involving 42 patients from 11 countries and 47 pregnancy records. Among these， 20 cases involved the use of fondaparinux for the prevention of pregnancy-related venous thromboembolism （VTE）， while 27 cases were fondaparinux treatment due to related conditions. A total of 29 occurrences of the patients were treated with fondaparinux due to a （family） history of VTE. Nine occurrences of complicated pregnancies were reported， and 35 patients had records of comorbidities or relevant medical histories. The adverse events that occurred during pregnancy with the use of fondaparinux include postpartum hemorrhage （7 cases） and excessive anticoagulation caused by inappropriate dosage （1 case）. Among the 7 cases of postpartum hemorrhage， 3 cases had a blood loss of no less than 1 000 mL （including 2 cases with uterine atony）， 3 cases had a drug discontinuation time of ≤12 h. CONCLUSIONS Based on the existing literature， the safety of fondaparinux during pregnancy is generally manageable， with the main adverse event being postpartum hemorrhage. The dosage， interval between discontinuation，comorbidities/medical history， and concomitant medications of fondaparinux may be the main causes of its adverse events.